TrialNature communications2024

Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial.

Xun Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.